PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team
Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
The Ketchum veteran joined the nonprofit healthcare system in mid-2014.
A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."
Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.
Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet
After Bill McEllen's departure, the company promoted Mark Willmann to lead the agency.
FitzPatrick is departing the company as it evaluates its 150 agency partnerships.
Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets
Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.